Related Experiment Video
Updated: Jul 6, 2026
04:22
Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
[Sex differences in Alzheimer's disease]
Reinhold Schmidt1, Eva Kienbacher, Thomas Benke
1Univ.-Klinik für Neurologie, Medizinische Universität Graz. reinhold.schmidt@meduni-graz.at
Summary
Alzheimer disease (AD) is more prevalent in women, with higher incidence and varied cognitive and behavioral symptoms. Gender influences AD presentation and caregiving, with women disproportionately affected and providing care.
Area of Science:
- Neurology
- Gerontology
- Epidemiology
Context:
- Alzheimer disease (AD) exhibits higher prevalence and incidence in women compared to men.
- Gender-specific differences are observed in cognitive deficits, behavioral symptoms, and caregiving roles in AD patients.
- Biological factors, including brain morphology, cognitive reserve, and hormonal changes, may underlie these sex differences.
Purpose:
- To explore gender-specific differences in Alzheimer disease prevalence, incidence, and clinical presentation.
- To investigate potential biological and social factors contributing to sex differences in AD.
- To highlight the significant role of women in AD caregiving.
Summary:
- Women experience higher rates of Alzheimer disease (AD) across age groups, with notable differences in cognitive and behavioral manifestations.
- Biological factors like brain structure and hormonal changes, alongside social factors such as caregiving responsibilities, contribute to gender disparities in AD.
- Women constitute a majority of AD patients receiving benefits and are the primary caregivers in both familial and institutional settings.
Impact:
- Understanding gender differences in AD is crucial for developing targeted diagnostic and therapeutic strategies.
- This research underscores the need for gender-sensitive approaches in AD research and clinical practice.
- Recognizing the burden on female caregivers is essential for providing adequate support and resources.
More Related Videos
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.